Logo image of AMRN

AMARIN CORP PLC -ADR (AMRN) Stock Fundamental Analysis

USA - NASDAQ:AMRN - US0231114044 - ADR

19.46 USD
-0.15 (-0.79%)
Last: 10/23/2025, 8:00:01 PM
19.4523 USD
-0.01 (-0.04%)
After Hours: 10/23/2025, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AMRN. AMRN was compared to 534 industry peers in the Biotechnology industry. The financial health of AMRN is average, but there are quite some concerns on its profitability. AMRN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

AMRN had negative earnings in the past year.
In the past year AMRN has reported a negative cash flow from operations.
AMRN had negative earnings in 4 of the past 5 years.
In the past 5 years AMRN reported 4 times negative operating cash flow.
AMRN Yearly Net Income VS EBIT VS OCF VS FCFAMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

AMRN has a Return On Assets of -15.46%. This is amongst the best in the industry. AMRN outperforms 81.09% of its industry peers.
The Return On Equity of AMRN (-22.28%) is better than 82.96% of its industry peers.
Industry RankSector Rank
ROA -15.46%
ROE -22.28%
ROIC N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
AMRN Yearly ROA, ROE, ROICAMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800

1.3 Margins

AMRN has a Gross Margin of 54.10%. This is in the better half of the industry: AMRN outperforms 76.59% of its industry peers.
AMRN's Gross Margin has declined in the last couple of years.
AMRN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
AMRN Yearly Profit, Operating, Gross MarginsAMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
AMRN has more shares outstanding than it did 1 year ago.
AMRN has more shares outstanding than it did 5 years ago.
AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMRN Yearly Shares OutstandingAMRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
AMRN Yearly Total Debt VS Total AssetsAMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.54, we must say that AMRN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.54, AMRN perfoms like the industry average, outperforming 51.87% of the companies in the same industry.
AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.54
ROIC/WACCN/A
WACC7.59%
AMRN Yearly LT Debt VS Equity VS FCFAMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

AMRN has a Current Ratio of 3.26. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
AMRN's Current ratio of 3.26 is on the low side compared to the rest of the industry. AMRN is outperformed by 61.05% of its industry peers.
A Quick Ratio of 2.34 indicates that AMRN has no problem at all paying its short term obligations.
AMRN has a worse Quick ratio (2.34) than 67.98% of its industry peers.
Industry RankSector Rank
Current Ratio 3.26
Quick Ratio 2.34
AMRN Yearly Current Assets VS Current LiabilitesAMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

AMRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.75%.
The Revenue for AMRN has decreased by -17.17% in the past year. This is quite bad
Measured over the past years, AMRN shows a very negative growth in Revenue. The Revenue has been decreasing by -11.86% on average per year.
EPS 1Y (TTM)-18.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1074.71%
Revenue 1Y (TTM)-17.17%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%7.78%

3.2 Future

The Earnings Per Share is expected to grow by 17.76% on average over the next years. This is quite good.
AMRN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.83% yearly.
EPS Next Y-0.15%
EPS Next 2Y29.62%
EPS Next 3Y17.33%
EPS Next 5Y17.76%
Revenue Next Year-4.55%
Revenue Next 2Y-8.82%
Revenue Next 3Y-6.09%
Revenue Next 5Y26.83%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AMRN Yearly Revenue VS EstimatesAMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AMRN Yearly EPS VS EstimatesAMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AMRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMRN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMRN Price Earnings VS Forward Price EarningsAMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMRN Per share dataAMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

A more expensive valuation may be justified as AMRN's earnings are expected to grow with 17.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.62%
EPS Next 3Y17.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMRN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMARIN CORP PLC -ADR

NASDAQ:AMRN (10/23/2025, 8:00:01 PM)

After market: 19.4523 -0.01 (-0.04%)

19.46

-0.15 (-0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2025-07-30/bmo
Earnings (Next)10-28 2025-10-28
Inst Owners17.98%
Inst Owner Change0.02%
Ins Owners0.77%
Ins Owner Change0.54%
Market Cap402.49M
Revenue(TTM)219.36M
Net Income(TTM)-103588000
Analysts42.5
Price Target11.22 (-42.34%)
Short Float %1.98%
Short Ratio6.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)217.77%
Min EPS beat(2)-30.72%
Max EPS beat(2)466.25%
EPS beat(4)2
Avg EPS beat(4)115.68%
Min EPS beat(4)-30.72%
Max EPS beat(4)466.25%
EPS beat(8)5
Avg EPS beat(8)81.97%
EPS beat(12)7
Avg EPS beat(12)66.33%
EPS beat(16)9
Avg EPS beat(16)43.98%
Revenue beat(2)1
Avg Revenue beat(2)6.91%
Min Revenue beat(2)-18.83%
Max Revenue beat(2)32.65%
Revenue beat(4)2
Avg Revenue beat(4)19.27%
Min Revenue beat(4)-18.83%
Max Revenue beat(4)70.07%
Revenue beat(8)5
Avg Revenue beat(8)16.14%
Revenue beat(12)8
Avg Revenue beat(12)11.62%
Revenue beat(16)9
Avg Revenue beat(16)6.62%
PT rev (1m)0%
PT rev (3m)-31.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)31.08%
EPS NY rev (1m)11.48%
EPS NY rev (3m)3.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.83
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB 0.89
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS10.61
BVpS22.48
TBVpS21.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.46%
ROE -22.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.1%
FCFM N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.26
Quick Ratio 2.34
Altman-Z -1.54
F-Score3
WACC7.59%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1074.71%
EPS Next Y-0.15%
EPS Next 2Y29.62%
EPS Next 3Y17.33%
EPS Next 5Y17.76%
Revenue 1Y (TTM)-17.17%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%7.78%
Revenue Next Year-4.55%
Revenue Next 2Y-8.82%
Revenue Next 3Y-6.09%
Revenue Next 5Y26.83%
EBIT growth 1Y-90.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.04%
EBIT Next 3Y18.17%
EBIT Next 5YN/A
FCF growth 1Y32.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.99%
OCF growth 3YN/A
OCF growth 5YN/A